Literature DB >> 25002310

You're not the one: treating subjects co-infected with hepatitis C genotypes 2 and 3 and human immunodeficiency virus.

Brian L Pearlman1, Tanna H Lim.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25002310     DOI： 10.1007/s10620-014-3270-8

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  15 in total

1.  Rates and predictors of response to anti-viral treatment for hepatitis C virus in HIV/HCV co-infection in a nationwide study of 619 patients.

Authors:  G N Ioannou; J D Scott; Y Yang; P K Green; L A Beste
Journal:  Aliment Pharmacol Ther       Date:  2013-10-16       Impact factor: 8.171

2.  Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.

Authors:  Lay Lay Win; Paul James; David K Wong
Journal:  Dig Dis Sci       Date:  2014-05-21       Impact factor: 3.199

3.  The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients.

Authors:  Mattias Mandorfer; Karin Neukam; Thomas Reiberger; Berit A Payer; Antonio Rivero; Massimo Puoti; Christoph Boesecke; Axel Baumgarten; Anna Grzeszczuk; Robert Zangerle; Dirk Meyer-Olson; Jürgen K Rockstroh; Michael Trauner; Juan A Pineda; Markus Peck-Radosavljevic
Journal:  AIDS       Date:  2013-11-13       Impact factor: 4.177

4.  Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

Authors:  Stefan Zeuzem; Geoffrey M Dusheiko; Riina Salupere; Alessandra Mangia; Robert Flisiak; Robert H Hyland; Ari Illeperuma; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Ola Weiland; Hendrik W Reesink; Peter Ferenci; Christophe Hézode; Rafael Esteban
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

Review 5.  Discovery of the hepatitis C virus.

Authors:  Michael Houghton
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

6.  Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.

Authors:  Nezam Afdhal; Stefan Zeuzem; Paul Kwo; Mario Chojkier; Norman Gitlin; Massimo Puoti; Manuel Romero-Gomez; Jean-Pierre Zarski; Kosh Agarwal; Peter Buggisch; Graham R Foster; Norbert Bräu; Maria Buti; Ira M Jacobson; G Mani Subramanian; Xiao Ding; Hongmei Mo; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Alessandra Mangia; Patrick Marcellin
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

7.  Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Authors:  Vincent Lo Re; Michael J Kallan; Janet P Tate; A Russell Localio; Joseph K Lim; Matthew Bidwell Goetz; Marina B Klein; David Rimland; Maria C Rodriguez-Barradas; Adeel A Butt; Cynthia L Gibert; Sheldon T Brown; Lesley Park; Robert Dubrow; K Rajender Reddy; Jay R Kostman; Brian L Strom; Amy C Justice
Journal:  Ann Intern Med       Date:  2014-03-18       Impact factor: 25.391

8.  A 24-week treatment strategy with pegylated interferon/ribavirin in HIV/hepatitis C virus genotype 3-coinfected patients who achieved a rapid virologic response results in a high sustained virologic response rate.

Authors:  Antonio Rivero-Juarez; Luis F López-Cortés; Angela Camacho; Jose A Mira; Francisco Téllez; Manuel Marquez; Dolores Merino; Juan A Pineda; Antonio Rivero
Journal:  Clin Infect Dis       Date:  2013-09-24       Impact factor: 9.079

Review 9.  HIV and hepatitis C virus co-infection.

Authors:  Jürgen Kurt Rockstroh; Ulrich Spengler
Journal:  Lancet Infect Dis       Date:  2004-07       Impact factor: 25.071

10.  Diagnosis, management, and treatment of hepatitis C: an update.

Authors:  Marc G Ghany; Doris B Strader; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.